Partial Cystectomy for Muscle-Invasive Bladder Cancer
Authors:
- Peter S. PalenciaPPPeter S. Palencia
- Nethusan SivanesanNSNethusan Sivanesan
- Syed RahmanSRSyed Rahman
- Fady GhaliFGFady Ghali
- David HesseDHDavid Hesse
- John ColbergJCJohn Colberg
- Ashwin SridharASAshwin Sridhar
- John D. KellyJKJohn D. Kelly
- Byron H. LeeBLByron H. Lee
- Ashish M. KamatAshish M. Kamat
- Wei-Shen TanWTWei-Shen Tan
Open Access
Abstract
Partial cystectomy is a surgical bladder-sparing option for selected patients with muscle-invasive bladder cancer (MIBC), urachal adenocarcinoma and diverticular bladder tumors. Partial cystectomy hold several advantages. It allows for definite pathology and accurate staging while avoiding side effects from radiation therapy and preserves the option for salvage radical therapy (radical cystectomy or radical radiotherapy). Patients should have a CT urogram, prostatic urethral biopsy and mapping biopsies or blue light cystoscopy to rule out multifocal disease or CIS. Small solitary MIBC patients without carcinoma in situ in an area of the bladder where resection can be performed with negative margin would be the ideal candidates for partial cystectomy. Neoadjuvant systemic therapy is recommended for patients undergoing partial cystectomy. Partial cystectomy can be performed either by open or robotic approaches. When compared to radical cystectomy, partial cystectomy affords a lower complication rate and length of stay and better quality of life. Recurrence-free survival, cancer-specific survival and overall survival at 5 years is 39–67%, 62–84% and 45–70%, respectively. Following partial cystectomy, patients should have three monthly cystoscopy and urinary cytology for the first 24 months followed by 6-monthly cystoscopy for year 3 and 4 and then yearly for life. Cross-sectional imaging should be performed every 3–6 months for the first 2–3 years and then annually for 5 years.Keywords
This publication has 42 references indexed in Scilit:
- Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder CancerJAMA, 2022
- Clinical outcomes and patterns of population‐based management of urachal carcinoma of the bladder: An analysis of the National Cancer DatabaseCancer Medicine, 2022
- Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical OutcomesEuropean Urology Focus, 2020
- Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital ExperienceEuropean Urology, 2017
- Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder CarcinomaJAMA Oncology, 2016
- Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and AsiaCancer Treatment Reviews, 2016
- Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw DataEuropean Urology, 2013
- Clinical value of FDG PET or PET/CT in urinary bladder cancer: A systemic review and meta-analysisEuropean Journal of Radiology, 2012
- Outcome of Patients Who Refuse Cystectomy after Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder CancerEuropean Urology, 2008
- Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancyCancer, 2006